Skip to main content
Premium Trial:

Request an Annual Quote

GE to Commercialize Cytori's Stem Cell Technology in North America

NEW YORK (GenomeWeb News) – GE Healthcare and San Diego-based Cytori jointly announced today that GE will commercialize Cytori's StemSource technology in North America for the stem cell banking and research markets.

The StemSource technology automates and processes stem and regenerative cells found in adipose tissue and cryopreserves them directly for research purposes. The term of the pact is 18 months and begins in the current quarter. The agreement does not include Cytori's Celution System for cosmetic and reconstructive surgery, which is currently under Food and Drug Admin istration review.

The North American agreement follows a similar alliance signed between the firms in January covering 10 European countries. That deal includes both the StemSource and Celution technologies.

"Our US sales team, like that in Europe, is seeing growing customer demand for adipose-related cell technology, both from our existing stem cell banking customers as well as our research customers involved in the development of cell therapies," Konstantin Fiedler, general manager of cell technologies at GE Healthcare, said in a statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.